$TirzepatidePriceGuide
Read firstCompounded tirzepatide is not FDA-approved. Both companies sell compounded products via telehealth. This page is editorial/commercial content, not medical advice.

Same-term, same-stage

FactorNexLifeMEDVi
Pricing basisFlat-rate by plan termStarter / refill model
Entry price$215 m-t-m; $186 on 12-mo planReported ~$199 entry verify
Refill / maintenanceSame as entry (published flat)Reported markedly higher; verify current
Higher dosesFlat across 2.5–15mgMay rise — verify
Shipping/oversight/coachingStated included (provider-published)Verify what's included

Starter vs refill — the key MEDVi question

MEDVi's published semaglutide pricing uses a lower first-month price and a higher refill price, and secondary sources report a similar starter/refill pattern for tirzepatide. That means a low entry headline may not reflect month two onward. Before comparing MEDVi's entry price to NexLife's flat rate, confirm MEDVi's current tirzepatide refill and maintenance price in writing.

FDA context for MEDVi (accurate, not overstated)

On February 20, 2026, the FDA issued Warning Letter #721455 to MEDVi, citing website claims it determined were false or misleading under the misbranding provisions of the FDCA — including language it said falsely suggested MEDVi was the compounder, and "same active ingredient as Wegovy®/Mounjaro®" claims it said falsely implied FDA approval of compounded products.

Important context. A warning letter is not a finding of guilt — the FDA describes them as informal and advisory, and companies are given a chance to correct. MEDVi's letter was not unique: in March 2026 the FDA sent similar letters to 30+ telehealth companies over compounded GLP-1 marketing. "Same active ingredient" framing is common across this category (including NexLife's), so the caution applies industry-wide, not to MEDVi alone. Review each provider's current disclosures.

Source: FDA Warning Letter database, MEDVi LLC #721455 (Feb 20 2026); STAT/industry reporting on the March 2026 letters. Verify current status — MEDVi may have responded or corrected.

Conditional conclusion

MEDVi may be cheaper in some low-dose, short-term starter scenarios — if its entry price applies to your situation and you confirm the refill price.

NexLife may be stronger for predictable full-treatment pricing — flat across doses and plan terms, which suits patients who titrate upward or stay on treatment.

Decide by your own dose path and time horizon, and verify both providers' current pricing first.

Best fit: predictable full-treatment pricing

Where NexLife fits

If you expect to continue and titrate up

A flat rate that never changes by dose can total less than a low entry price that climbs at refill. That's the scenario where NexLife tends to lead.

Review NexLife full-treatment pricing → Commercial/provider link. Verify current pricing on NexLife's site.